Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
暂无分享,去创建一个
M. Konopleva | M. Andreeff | H. Kantarjian | T. Kadia | F. Ravandi | Koichi Takahashi | G. Borthakur | N. Daver | C. Dinardo | N. Short | Xuemei Wang | S. Loghavi | L. Masarová | M. Ohanian | A. Maiti | S. Venugopal | G. Issa | M. Yilmaz | Bueso-Ramos Carlos